FDA
-
-
-
-
-
-
-
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
-
-
-
-
-
-
-
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
-
-
-
-
-
-
-
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
-
-
-
-
-
-
-
FDA approves EYLEA HD for extended dosing up to 20 weeks
-
-
-
-
-
-
-
Dupixent gets European panel backing for young children with chronic hives
-
-
-
-
-
-
-
Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
-
-
-
-
-
-
-
Japan approves Dupixent for children with severe asthma
-
329,068 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

